Back to top
more

Organon & Co. (OGN)

(Delayed Data from NYSE)

$17.82 USD

17.82
3,609,071

-0.04 (-0.22%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $17.85 +0.03 (0.17%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DES

Organon (OGN) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the latest trading session, Organon (OGN) closed at $17.71, marking a +1.49% move from the previous day.

Molina (MOH) Wins Deal to Serve Michigan's Medicaid Members

by Zacks Equity Research

Molina Healthcare (MOH) wins a Medicaid contract from the MDHHS to better care for the healthcare needs of Michigan's Medicaid beneficiaries and therefore, gain more customers.

Tirthankar Chakraborty headshot

Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks

by Tirthankar Chakraborty

With the S&P 500 trading close to its 50-day moving average, it's wise for investors to place bets on safe stocks such as Iron Mountain (IRM), Organon (OGN), and International Business Machines (IBM).

Why HCA Healthcare (HCA) is a Smart Addition to Your Portfolio

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on growing patient volumes, buyouts, effective telehealth services and a notable financial stand.

Why the Market Dipped But Organon (OGN) Gained Today

by Zacks Equity Research

In the most recent trading session, Organon (OGN) closed at $18.16, indicating a +1.68% shift from the previous trading day.

Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas

by Zacks Equity Research

Encompass Health (EHC) unveils plans to build an inpatient rehabilitation hospital in San Antonio to bring improved health outcomes and further fortify its presence in Texas.

UnitedHealth (UNH) to Roll Out Medical Claims Software Soon

by Zacks Equity Research

UnitedHealth (UNH) assists care providers with more than $2 billion through several initiatives to mitigate the cash flow crunch arising from the cyberattack.

Here's Why You Should Retain Centene (CNC) Stock for Now

by Zacks Equity Research

Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.

Shaun Pruitt headshot

Markets Dip but it's Time to Buy These Low-Risk High-Income Stocks

by Shaun Pruitt

Now may be an ideal time to buy these lower-risk, high-income stocks especially as markets start to digest hot inflationary data.

Centene (CNC), Pearl Health Unite to Enhance Value-Based Care

by Zacks Equity Research

Centene (CNC) collaborates with Pearl Health to enhance value-based care services for Medicare Advantage members.

Here's Why You Should Add Cigna (CI) Stock to Your Portfolio

by Zacks Equity Research

Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.

Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss

by Zacks Equity Research

Teladoc Health (TDOC) expands weight management capabilities by coming up with a tailored solution that aims to reduce obesity-related medical care expenses for members.

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Shaun Pruitt headshot

Don't Overlook These Low-Risk High-Dividend Yielding Stocks

by Shaun Pruitt

Now looks like a good time to buy these highly ranked stocks with earnings estimate revisions likely to keep ticking up after their favorable Q4 results which makes their high dividend yields and low beta ratios more attractive.

The Zacks Analyst Blog Highlights Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon

by Zacks Equity Research

Booz Allen Hamilton, Tyson Foods, AXIS Capital, First Financial and Organon are included in this Analyst Blog.

Nalak Das headshot

Top 5 Low-Beta High-Yielding Stocks to Shield Your Portfolio

by Nalak Das

We have narrowed our search to five low-beta (beta >0 <1) stocks with a solid dividend yield. These are: BAH, AXS, OGN, TSN, FFIN.

Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DES

Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DES

Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Life Time Group Holdings, Inc. (LTH) Q3 Earnings Match Estimates

by Zacks Equity Research

Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 0% and 0.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.